health

Nature Medicine, Published online: 14 October 2024; doi:10.1038/d41591-024-00073-7

A study of over 2,000 people shows that interacting with a large language model reduced belief in conspiracy theories — including some related to COVID-19 — by providing tailored, one-on-one interactions and compelling evidence.

If you are in the process of planning your weight-loss diet, make sure to include cauliflower. Eating cauliflower for weight loss can be beneficial as this cruciferous vegetable is high in vital vitamins, minerals, and fiber, as well as low in calories. This allows you to enjoy a larger serving without feeling guilty. Additionally, cauliflower’s …

Continue reading "High in fiber, low in calories: Eating cauliflower for weight loss is a great idea"

Nature Medicine, Published online: 11 October 2024; doi:10.1038/s41591-024-03291-1

Research and interventions where children may disclose violence require effective, resourced and context-specific safeguarding response plans.

Nature Medicine, Published online: 11 October 2024; doi:10.1038/s41591-024-03332-9

Lassa fever is a cryptic viral disease that is spread predominantly from rodents to humans in West Africa. We estimated the health-economic burden associated with Lassa fever, highlighting the gains to population health and economies that could be afforded by Lassa vaccines, several of which are currently in development.

Nature Medicine, Published online: 10 October 2024; doi:10.1038/s41591-024-03318-7

This study explored how diverse factors including neurocognitive disorders, socioeconomic inequalities, pollution and gender disparities influence brain aging in underserved populations (groups with limited access to essential services such as healthcare and education). Using deep learning on EEG and fMRI data, we identified brain-age gaps as key markers of accelerated brain aging and their connections to macrosocial determinants of health.

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03304-z

The primary report of the EMBARK phase 3 trial, testing the AAV-based gene therapy delandistrogene moxeparvovec in Duchenne muscular dystrophy, did not meet its primary endpoint of improvement in NSAA mobility scores compared to placebo. Secondary endpoints show that the therapy was safe and associated with improvements in micro-dystrophin expression and in individual mobility scores.

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03296-w

Echocardiographic screening during routine pacemaker checkups identifies pacing-induced cardiomyopathy in more than one-third of patients, requiring multidisciplinary, guideline-directed follow-up care.

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03316-9

Delandistrogene moxeparvovec received FDA approval after a negative trial, which highlights the many complexities and challenges of drug development in this setting.

Nature Medicine, Published online: 09 October 2024; doi:10.1038/s41591-024-03325-8

Increases in antimicrobial resistance globally are likely to hit African countries the hardest. Strengthening the local infrastructure aimed at combating infection is the only way to counter it.

Nature Medicine, Published online: 08 October 2024; doi:10.1038/s41591-024-03270-6

Individuals with Parkinson’s disease treated with prasinezumab demonstrated slower motor progression over 4 years compared with an external comparator cohort derived from the Parkinson’s Progression Markers Initiative observational study.